Alumis Inc (ALMS)

$9.22 +0.04 (0.44%)
Market Cap 1.19B
Revenue (ttm) 24.05M
Net Income (ttm) -243.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,011.77%
Debt to Equity Ratio 0.00
Volume 4,027,500
Avg Vol 2,288,784
Day's Range N/A - N/A
Shares Out 129.44M
Stochastic %K 15%
Beta -0.81
Analysts Strong Sell
Price Target $32.12

Company Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibo...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 231 6625
Address:
280 East Grand Avenue, South San Francisco, United States
Thalassophile
Thalassophile Sep. 15 at 1:39 AM
$ALMS Christ
0 · Reply
Equibles
Equibles Sep. 15 at 12:36 AM
$ALMS Found it in the filings on Equibles. Alumis Inc. director AKKARAJU SRINIVAS reported buying 273,291 ALMS shares on September 8, 2026, worth about $2.9 million, in a non-derivative Form 4.
0 · Reply
bsprelude
bsprelude Sep. 14 at 5:06 PM
$ALMS Promising and reassuring presentation at Morgan Stanley 24th Annual Healthcare Conference plus insiders buying up shares… Buying the turnaround!! Bullish with a conservative PT of $15 by end of Sept!
0 · Reply
Jacki13
Jacki13 Sep. 14 at 4:34 PM
$ALMS buy 1k more , i am loss 20k but insider loss 3m , so dont give a f
0 · Reply
Michael675
Michael675 Sep. 12 at 2:01 PM
$RARE $ALMS Have a relaxing weekend, executives of the board(s)...and if you can't zone out even with sound knowledge of extremely high institutional ownership, jump on a flight to Scotland where I'll pitch you the next big thing- already making a return! 😆
0 · Reply
YouVSYou
YouVSYou Sep. 11 at 10:41 PM
YVY Weekend Setup Board $CRBP Monday obesity data with major ATM risk $BLSM cancer data Monday night and the cleanest paper $LPTH record revenue with a $110.9M backlog $LTRX post earnings continuation setting up $ALMS $9.7M insider accumulation but needs a chart reclaim Catalysts filings dilution and levels all checked Full setups posted in YVY Community 💫 Which one runs first
0 · Reply
marc1991
marc1991 Sep. 11 at 9:10 PM
$ALMS why there is n technical bounce?
0 · Reply
Jacki13
Jacki13 Sep. 11 at 8:01 PM
$ALMS no news , bought it and drop 8% , because i bought it
1 · Reply
Michael675
Michael675 Sep. 11 at 5:43 PM
$ALMS This seems like a buy!!! DISCLAIMER: Not guaranteed-maybe I should stick to writing books given past performance on here 😕 🤣. Go Bulls!!! https://uk.investing.com/news/stock-market-news/alumis-at-wells-fargo-conference-lupus-setback-sharpens-strategy-93CH-4861034
0 · Reply
JimCramerisadoofus
JimCramerisadoofus Sep. 11 at 5:43 PM
$ALMS I bought 909 at $11.00 and 1020 at $9.80. Will continue to buy an additional $10,000 for every $1.00 drop. No debt, 92% institutional ownership, and small short interest. I agree with Oppenheimer on this one. It will bounce back: "Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says"
0 · Reply
Latest News on ALMS
Alumis Transcript: Morgan Stanley 24th Annual Global Healthcare Conference

Sep 14, 2026, 7:45 AM EDT - 21 hours ago

Alumis Transcript: Morgan Stanley 24th Annual Global Healthcare Conference

Alumis Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Sep 9, 2026, 2:10 PM EDT - 5 days ago

Alumis Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Alumis Transcript: Wells Fargo 21st Annual Healthcare Conference

Sep 8, 2026, 11:00 AM EDT - 6 days ago

Alumis Transcript: Wells Fargo 21st Annual Healthcare Conference

Alumis to Participate in Upcoming September Investor Conferences

Sep 4, 2026, 8:00 AM EDT - 10 days ago

Alumis to Participate in Upcoming September Investor Conferences

Alumis downgraded to Neutral from Buy at Guggenheim

2026-09-03T09:40:13.000Z - 11 days ago

Alumis downgraded to Neutral from Buy at Guggenheim

Alumis rises 10.7%

2026-09-02T16:05:43.000Z - 12 days ago

Alumis rises 10.7%

Alumis price target lowered to $37 from $55 at Oppenheimer

2026-09-02T11:40:57.000Z - 12 days ago

Alumis price target lowered to $37 from $55 at Oppenheimer

Alumis price target lowered to $25 from $51 at Wells Fargo

2026-09-02T11:00:44.000Z - 12 days ago

Alumis price target lowered to $25 from $51 at Wells Fargo

Alumis price target lowered to $29 from $39 at Morgan Stanley

2026-09-02T10:55:54.000Z - 12 days ago

Alumis price target lowered to $29 from $39 at Morgan Stanley

Alumis upgraded to Buy from Neutral at H.C. Wainwright

2026-09-02T10:10:08.000Z - 12 days ago

Alumis upgraded to Buy from Neutral at H.C. Wainwright

Alumis price target lowered to $27 from $35 at Baird

2026-09-01T19:25:09.000Z - 13 days ago

Alumis price target lowered to $27 from $35 at Baird

Alumis price target lowered to $25 from $51 at Wells Fargo

2026-09-01T18:20:15.000Z - 13 days ago

Alumis price target lowered to $25 from $51 at Wells Fargo

A Lupus Drug Was a Failure and This Biotech Stock Is Down 58% Because of It

Sep 1, 2026, 1:23 PM EDT - 13 days ago

A Lupus Drug Was a Failure and This Biotech Stock Is Down 58% Because of It

Alumis falls -58.9%

2026-09-01T16:05:28.000Z - 13 days ago

Alumis falls -58.9%

Alumis falls -53.0%

2026-09-01T14:00:16.000Z - 13 days ago

Alumis falls -53.0%

Alumis eyes late-stage lupus study despite trial miss

Sep 1, 2026, 9:16 AM EDT - 13 days ago

Alumis eyes late-stage lupus study despite trial miss

Alumis Transcript: Study result

Sep 1, 2026, 8:30 AM EDT - 13 days ago

Alumis Transcript: Study result

Alumis Press release: Study result

Sep 1, 2026, 8:30 AM EDT - 13 days ago

Alumis Press release: Study result

Alumis Slides: Study result

Sep 1, 2026, 8:30 AM EDT - 13 days ago

Alumis Slides: Study result

Alumis reports LUMUS trial did not meet primary, secondary endpoints

2026-09-01T11:40:42.000Z - 13 days ago

Alumis reports LUMUS trial did not meet primary, secondary endpoints

Alumis trading halted, news pending

2026-09-01T11:30:14.000Z - 13 days ago

Alumis trading halted, news pending

Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)

Sep 1, 2026, 7:30 AM EDT - 13 days ago

Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)

Alumis reports Q2 revenue $1.66M, consensus $3.47M

2026-08-16T14:11:51.000Z - 4 weeks ago

Alumis reports Q2 revenue $1.66M, consensus $3.47M

Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements

Aug 13, 2026, 4:01 PM EDT - 4 weeks ago

Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements

Alumis Earnings release: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 4 weeks ago

Alumis Earnings release: Q2 2026

Alumis Quarterly report: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 4 weeks ago

Alumis Quarterly report: Q2 2026

Alumis announces topline results from ONWARD3 long-term extension study

2026-08-10T21:45:41.000Z - 5 weeks ago

Alumis announces topline results from ONWARD3 long-term extension study

Alumis Slides: Corporate presentation

Aug 1, 2026, 8:00 AM EDT - 6 weeks ago

Alumis Slides: Corporate presentation

Alumis management to meet with Cantor

2026-06-26T20:25:16.000Z - 2 months ago

Alumis management to meet with Cantor

Alumis rises 10.3%

2026-06-12T16:09:42.000Z - 3 months ago

Alumis rises 10.3%

Alumis price target raised to $40 from $38 at Chardan

2026-05-19T12:01:10.000Z - 3 months ago

Alumis price target raised to $40 from $38 at Chardan

Alumis Proxy statement: Proxy filing

May 18, 2026, 8:00 AM EDT - 3 months ago

Alumis Proxy statement: Proxy filing

Alumis Proxy statement: Proxy filing

May 18, 2026, 8:00 AM EDT - 3 months ago

Alumis Proxy statement: Proxy filing

Alumis price target raised to $39 from $38 at Morgan Stanley

2026-05-15T12:49:04.000Z - 4 months ago

Alumis price target raised to $39 from $38 at Morgan Stanley

Alumis Slides: Corporate presentation

May 15, 2026, 7:00 AM EDT - 4 months ago

Alumis Slides: Corporate presentation

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

May 14, 2026, 4:05 PM EDT - 4 months ago

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

Alumis Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 4 months ago

Alumis Earnings release: Q1 2026

Alumis Quarterly report: Q1 2026

May 14, 2026, 4:00 PM EDT - 4 months ago

Alumis Quarterly report: Q1 2026

Alumis Transcript: Study update

Mar 29, 2026, 7:00 PM EDT - 5 months ago

Alumis Transcript: Study update

Alumis Press release: Study update

Mar 29, 2026, 7:00 PM EDT - 5 months ago

Alumis Press release: Study update

Alumis Slides: Study update

Mar 29, 2026, 7:00 PM EDT - 5 months ago

Alumis Slides: Study update

Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Mar 28, 2026, 1:30 PM EDT - 5 months ago

Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

Mar 19, 2026, 4:05 PM EDT - 5 months ago

Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

Alumis Annual report: Q4 2025

Mar 19, 2026, 4:00 PM EDT - 5 months ago

Alumis Annual report: Q4 2025

Alumis Earnings release: Q4 2025

Mar 19, 2026, 4:00 PM EDT - 5 months ago

Alumis Earnings release: Q4 2025

Alumis Slides: Corporate presentation

Mar 19, 2026, 7:00 AM EDT - 5 months ago

Alumis Slides: Corporate presentation

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

Mar 18, 2026, 8:00 AM EDT - 6 months ago

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

Alumis Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 10:40 AM EDT - 6 months ago

Alumis Transcript: Leerink Global Healthcare Conference 2026

Alumis to Present at the Leerink Partners Global Healthcare Conference

Mar 2, 2026, 8:05 AM EST - 6 months ago

Alumis to Present at the Leerink Partners Global Healthcare Conference

Alumis Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 3:20 PM EST - 6 months ago

Alumis Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Alumis Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 12, 2026, 9:00 AM EST - 7 months ago

Alumis Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Alumis to Participate in Upcoming February Investor Conferences

Feb 5, 2026, 8:05 AM EST - 7 months ago

Alumis to Participate in Upcoming February Investor Conferences

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 9, 2026, 4:05 PM EST - 8 months ago

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Alumis Announces Pricing of Upsized Public Offering of Common Stock

Jan 7, 2026, 10:52 PM EST - 8 months ago

Alumis Announces Pricing of Upsized Public Offering of Common Stock

Alumis Announces Proposed Public Offering of Common Stock

Jan 6, 2026, 4:12 PM EST - 8 months ago

Alumis Announces Proposed Public Offering of Common Stock

Alumis Transcript: Study Result

Jan 6, 2026, 8:00 AM EST - 8 months ago

Alumis Transcript: Study Result

Alumis Press release: Study Result

Jan 6, 2026, 8:00 AM EST - 8 months ago

Alumis Press release: Study Result

Alumis Slides: Study Result

Jan 6, 2026, 8:00 AM EST - 8 months ago

Alumis Slides: Study Result

Alumis skin disease drug meets main goal of two late-stage trials

Jan 6, 2026, 7:07 AM EST - 8 months ago

Alumis skin disease drug meets main goal of two late-stage trials

Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Jan 6, 2026, 7:00 AM EST - 8 months ago

Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Jan 5, 2026, 5:00 PM EST - 8 months ago

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 13, 2025, 4:15 PM EST - 10 months ago

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Alumis Quarterly report: Q3 2025

Nov 13, 2025, 4:00 PM EST - 10 months ago

Alumis Quarterly report: Q3 2025

Alumis Earnings release: Q3 2025

Nov 13, 2025, 4:00 PM EST - 10 months ago

Alumis Earnings release: Q3 2025

Alumis Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 2:00 PM EST - 10 months ago

Alumis Transcript: Stifel 2025 Healthcare Conference

Alumis Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 1:30 PM EST - 10 months ago

Alumis Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Alumis to Participate in Upcoming November Investor Conferences

Nov 4, 2025, 8:00 AM EST - 10 months ago

Alumis to Participate in Upcoming November Investor Conferences

Alumis Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 16, 2025, 12:30 PM EDT - 12 months ago

Alumis Transcript: Stifel Virtual Immunology and Inflammation Forum

Alumis Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 4:50 PM EDT - 1 year ago

Alumis Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Alumis Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 5, 2025, 9:30 AM EDT - 1 year ago

Alumis Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Alumis Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 9:45 AM EDT - 1 year ago

Alumis Transcript: Cantor Global Healthcare Conference 2025

Alumis Slides: Corporate Presentation

Sep 3, 2025, 8:00 AM EDT - 1 year ago

Alumis Slides: Corporate Presentation

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:05 PM EDT - 1 year ago

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Alumis Quarterly report: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Alumis Quarterly report: Q2 2025

Alumis Earnings release: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Alumis Earnings release: Q2 2025

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Jul 24, 2025, 7:30 AM EDT - 1 year ago

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Jul 14, 2025, 4:05 PM EDT - 1 year ago

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Alumis Registration statement: Registration Filing

Jul 3, 2025, 8:00 AM EDT - 1 year ago

Alumis Registration statement: Registration Filing

Alumis Proxy statement: Proxy Filing

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Alumis Proxy statement: Proxy Filing

Alumis Proxy statement: Proxy Filing

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Alumis Proxy statement: Proxy Filing

Alumis Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 3:10 PM EDT - 1 year ago

Alumis Transcript: Jefferies Global Healthcare Conference 2025

Alumis to Present at the Jefferies Global Healthcare Investor Conference

May 29, 2025, 4:15 PM EDT - 1 year ago

Alumis to Present at the Jefferies Global Healthcare Investor Conference

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

May 29, 2025, 7:55 AM EDT - 1 year ago

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis Completes Merger with ACELYRIN

May 21, 2025, 9:10 AM EDT - 1 year ago

Alumis Completes Merger with ACELYRIN

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

May 14, 2025, 4:05 PM EDT - 1 year ago

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Quarterly report: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Alumis Quarterly report: Q1 2025

Alumis Earnings release: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Alumis Earnings release: Q1 2025

Alumis Stockholders Approve Merger with ACELYRIN

May 13, 2025, 1:00 PM EDT - 1 year ago

Alumis Stockholders Approve Merger with ACELYRIN

Alumis and ACELYRIN Announce Amended Merger Agreement

Apr 21, 2025, 6:30 AM EDT - 1 year ago

Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

Apr 16, 2025, 5:31 PM EDT - 1 year ago

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

SLRN

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Apr 4, 2025, 4:34 PM EDT - 1 year ago

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Mar 25, 2025, 2:30 AM EDT - 1 year ago

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Mar 19, 2025, 4:05 PM EDT - 1 year ago

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis Annual report: Q4 2024

Mar 19, 2025, 4:00 PM EDT - 1 year ago

Alumis Annual report: Q4 2024

Alumis Earnings release: Q4 2024

Mar 19, 2025, 4:00 PM EDT - 1 year ago

Alumis Earnings release: Q4 2024

Alumis Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 10:40 AM EDT - 1 year ago

Alumis Transcript: Leerink’s Global Healthcare Conference 2025

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Mar 8, 2025, 9:00 AM EST - 1 year ago

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Mar 4, 2025, 9:01 AM EST - 1 year ago

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Mar 4, 2025, 9:00 AM EST - 1 year ago

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

SLRN

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Feb 28, 2025, 9:08 AM EST - 1 year ago

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Feb 27, 2025, 4:15 PM EST - 1 year ago

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Alumis Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 3:20 PM EST - 1 year ago

Alumis Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 10, 2025, 4:45 PM EST - 1 year ago

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

Feb 7, 2025, 3:22 PM EST - 1 year ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

SLRN

Alumis Transcript: M&A Announcement

Feb 6, 2025, 5:00 PM EST - 1 year ago

Alumis Transcript: M&A Announcement

Alumis Press release: M&A Announcement

Feb 6, 2025, 5:00 PM EST - 1 year ago

Alumis Press release: M&A Announcement

Alumis Slides: M&A Announcement

Feb 6, 2025, 5:00 PM EST - 1 year ago

Alumis Slides: M&A Announcement

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Feb 6, 2025, 4:15 PM EST - 1 year ago

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Strengthens Leadership Team with Key Appointments

Jan 28, 2025, 8:00 AM EST - 1 year ago

Alumis Strengthens Leadership Team with Key Appointments

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Nov 13, 2024, 4:05 PM EST - 1 year ago

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Alumis Quarterly report: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Alumis Quarterly report: Q3 2024

Alumis Earnings release: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Alumis Earnings release: Q3 2024

Alumis Transcript: Guggenheim's Inaugural Healthcare Innovation Conference

Nov 12, 2024, 2:00 PM EST - 1 year ago

Alumis Transcript: Guggenheim's Inaugural Healthcare Innovation Conference

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Sep 27, 2024, 9:00 AM EDT - 1 year ago

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Alumis Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 10:55 AM EDT - 1 year ago

Alumis Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Aug 13, 2024, 4:05 PM EDT - 2 years ago

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Alumis Quarterly report: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Alumis Quarterly report: Q2 2024

Alumis Earnings release: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Alumis Earnings release: Q2 2024

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Jul 29, 2024, 8:00 AM EDT - 2 years ago

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Jun 28, 2024, 12:58 PM EDT - 2 years ago

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Jun 28, 2024, 12:43 AM EDT - 2 years ago

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Alumis Announces Pricing of Initial Public Offering

Jun 27, 2024, 11:57 PM EDT - 2 years ago

Alumis Announces Pricing of Initial Public Offering

Thalassophile
Thalassophile Sep. 15 at 1:39 AM
$ALMS Christ
0 · Reply
Equibles
Equibles Sep. 15 at 12:36 AM
$ALMS Found it in the filings on Equibles. Alumis Inc. director AKKARAJU SRINIVAS reported buying 273,291 ALMS shares on September 8, 2026, worth about $2.9 million, in a non-derivative Form 4.
0 · Reply
bsprelude
bsprelude Sep. 14 at 5:06 PM
$ALMS Promising and reassuring presentation at Morgan Stanley 24th Annual Healthcare Conference plus insiders buying up shares… Buying the turnaround!! Bullish with a conservative PT of $15 by end of Sept!
0 · Reply
Jacki13
Jacki13 Sep. 14 at 4:34 PM
$ALMS buy 1k more , i am loss 20k but insider loss 3m , so dont give a f
0 · Reply
Michael675
Michael675 Sep. 12 at 2:01 PM
$RARE $ALMS Have a relaxing weekend, executives of the board(s)...and if you can't zone out even with sound knowledge of extremely high institutional ownership, jump on a flight to Scotland where I'll pitch you the next big thing- already making a return! 😆
0 · Reply
YouVSYou
YouVSYou Sep. 11 at 10:41 PM
YVY Weekend Setup Board $CRBP Monday obesity data with major ATM risk $BLSM cancer data Monday night and the cleanest paper $LPTH record revenue with a $110.9M backlog $LTRX post earnings continuation setting up $ALMS $9.7M insider accumulation but needs a chart reclaim Catalysts filings dilution and levels all checked Full setups posted in YVY Community 💫 Which one runs first
0 · Reply
marc1991
marc1991 Sep. 11 at 9:10 PM
$ALMS why there is n technical bounce?
0 · Reply
Jacki13
Jacki13 Sep. 11 at 8:01 PM
$ALMS no news , bought it and drop 8% , because i bought it
1 · Reply
Michael675
Michael675 Sep. 11 at 5:43 PM
$ALMS This seems like a buy!!! DISCLAIMER: Not guaranteed-maybe I should stick to writing books given past performance on here 😕 🤣. Go Bulls!!! https://uk.investing.com/news/stock-market-news/alumis-at-wells-fargo-conference-lupus-setback-sharpens-strategy-93CH-4861034
0 · Reply
JimCramerisadoofus
JimCramerisadoofus Sep. 11 at 5:43 PM
$ALMS I bought 909 at $11.00 and 1020 at $9.80. Will continue to buy an additional $10,000 for every $1.00 drop. No debt, 92% institutional ownership, and small short interest. I agree with Oppenheimer on this one. It will bounce back: "Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says"
0 · Reply
glaucio
glaucio Sep. 11 at 4:37 PM
$ALMS yr chart is telling something
0 · Reply
marc1991
marc1991 Sep. 11 at 3:58 PM
$ALMS where is the bottom here? With such a low RSI …
1 · Reply
Thalassophile
Thalassophile Sep. 11 at 2:42 PM
$ALMS Just bought in at 9.88....of course. lol
3 · Reply
spaarrow1
spaarrow1 Sep. 11 at 8:40 AM
$ALMS you guys have to stop sellibg every 50 cents up
0 · Reply
Dameistro
Dameistro Sep. 10 at 1:29 PM
$ALMS 11+ today!!
0 · Reply
Cairnsman
Cairnsman Sep. 10 at 1:28 PM
$ALMS
0 · Reply
YouVSYou
YouVSYou Sep. 10 at 11:06 AM
$ALMS nice form 4
0 · Reply
aletz
aletz Sep. 10 at 10:50 AM
$ALMS insider buy!! $10.5M worth open market between Sep 4~8 Huge sale price
0 · Reply
biotechdeeppro
biotechdeeppro Sep. 10 at 3:52 AM
$ALMS one of the insiders bought big amount.
1 · Reply
Cryptobearcat
Cryptobearcat Sep. 10 at 12:25 AM
$ALMS New to this ticker guys, why did it drop 57%? Was there more nuance to missing the target? Appreciate any input.
3 · Reply
TopTierNewswire
TopTierNewswire Sep. 9 at 11:02 PM
$PINS kept drilling further down. The top short opportunity from our AI model has continued to reap more profit.
0 · Reply